Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2024-04-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于续聘会计师事务所的公告
Regulatory Filings Classification · 90% confidence The document is an announcement regarding the reappointment of an accounting firm (信永中和会计师事务所) for the 2024 fiscal year audit and internal control audit. It details the firm's qualifications, personnel, audit fees, and the approval process by the board and audit committee. The document does not contain actual financial statements or audit results but is a formal notice about the appointment of the auditor, which is a regulatory announcement related to audit services. The document length is 2590 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, it fits best under the category of Audit Report / Information (AR), as it relates to audit information but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the auditor and not the audit report or results, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a formal disclosure about audit firm appointment rather than the audit report itself.
2024-04-22 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance of the accounting firm for the year 2023. It discusses the audit firm's qualifications, independence, audit procedures, and the committee's supervision of the audit process. It does not contain the full annual report or financial statements but rather an assessment and oversight report related to the audit. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding the full Annual Report (10-K). The document length is 2428 characters, which is relatively short but contains substantive content about audit oversight rather than just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-22 Chinese
2023年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制自我评价报告' which translates to '2023 Annual Internal Control Self-Evaluation Report' of 拓新药业集团股份有限公司. It discusses the company's internal control system, evaluation of its effectiveness, risk assessment, control activities, and governance structure. The content is detailed and comprehensive, covering internal control policies, risk management, organizational structure, and control procedures. It is not a financial statement or earnings release but a report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it relates to audit and internal control results. The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or certification. Therefore, it fits best under the Audit Report / Information category (AR). FY 2023
2024-04-22 Chinese
独立董事2023年度述职报告（靳焱顺）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for a company, detailing the independent director's attendance at meetings, opinions on various board matters, committee participation, and efforts to protect investor rights during the year 2023. It is a detailed report on the independent director's activities and responsibilities over the year, not a general annual report or financial statement. It does not contain financial data or audit results but focuses on board/management information, specifically the independent director's role and duties. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 3071 characters, which is consistent with a detailed report but not a full annual report or audit report.
2024-04-22 Chinese
关于募集资金2023年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by the company in 2023. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange related to the management and use of raised funds. The content includes specifics on the amount raised, usage, balance, changes in project implementation, and compliance with regulatory requirements. The document is titled as a "专项报告" (special report) on the use of raised funds for the year 2023. This type of report is typically classified as a Capital/Financing Update (CAP) because it focuses on fundraising proceeds, their management, and usage rather than being a full annual or interim financial report. It is not an announcement of a report publication, nor is it a certification or a general regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-04-22 Chinese
关于调整公司组织架构的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the company regarding an adjustment to its organizational structure, approved by the board of directors. It includes a description of the internal management changes and an organizational chart attachment. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no shareholder voting results. The content focuses on management and board structure changes, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the appropriate classification is MANG with high confidence.
2024-04-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.